ADMA Inquiry News: ADMA Biologics Investors are Notified of
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics, Inc. for potential federal securities law violations following a report by Culper Research. The report alleges that ADMA Biologics' reported 20% revenue growth in 2025 was a result of a channel stuffing scheme and not genuine demand, causing the stock to drop by 29%. Investors who experienced losses are encouraged to contact BFA Law for information on their legal options.
B Group Increases Stake in ADMA Biologics by 750,000 Shares
B Group recently increased its stake in ADMA Biologics by purchasing 750,000 additional shares for $11.84 million, bringing its total holding to 3,207,542 shares valued at $28.90 million. This acquisition demonstrates B Group's continued confidence in ADMA, despite a 58% stock price drop over the past year. B Group's decision is supported by ADMA's resilient financial performance, including a 22% increase in adjusted net income and a 28% surge in ASCENIV product revenue.
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
B Group, Inc. increased its stake in ADMA Biologics (NASDAQ: ADMA) by 750,000 shares, a purchase valued at an estimated $11.84 million, despite the stock being down 58% over the past year. This transaction made ADMA Biologics the largest holding in B Group's 13F assets under management. While BIVIGAM sales declined, ADMA's Q1 adjusted net income and EBITDA increased significantly, and ASCENIV revenue jumped 28% year over year, leading B Group to see long-term opportunity in the stock.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Pomerantz LLP is investigating potential claims of securities fraud or unlawful business practices against ADMA Biologics, Inc. on behalf of its investors. The investigation follows a short report by Culper Research and a downgrade by Cantor Fitzgerald, both criticizing ADMA's business practices and financial reporting. These events, coupled with ADMA's withdrawal of long-term financial guidance, led to significant drops in the company's stock price.
ADMA Securities Investigation: ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law
BFA Law is investigating ADMA Biologics for potential securities fraud after its stock dropped 29%. This drop followed a Culper Research report alleging that ADMA Biologics engaged in channel stuffing to falsely report 20% revenue growth in 2025, when true growth would have been a 3% decline. Investors who purchased ADMA Biologics stock are encouraged to contact BFA Law regarding their legal options.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ...
The Rosen Law Firm is investigating potential securities claims on behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) shareholders who suffered losses. This investigation follows allegations that the company may have issued misleading business information, specifically concerning a March 2023 report by Culper Research accusing ADMA Biologics of channel stuffing to inflate revenue growth. The news of this report led to a 16.6% drop in ADMA Biologics' stock on March 28, 2023.
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA Biologics' shares have significantly declined following a first-quarter earnings report where the company lowered its 2026 revenue and net income guidance due to increased competition and aggressive pricing in the standard immunoglobulin market. While its lead product, Asceniv, shows strong demand, the overall challenges in the plasma-derived products sector, combined with negative investor sentiment and declining earnings estimates, suggest that ADMA stock currently has an unfavorable risk-reward balance, leading to a "Strong Sell" rating from Zacks.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Pomerantz LLP is investigating ADMA Biologics, Inc. (ADMA) on behalf of investors for potential securities fraud. This follows a Culper Research report alleging channel stuffing, a Cantor Fitzgerald downgrade due to dissatisfaction with ADMA's response, and ADMA's subsequent withdrawal of long-term financial guidance, all of which led to significant drops in the company's stock price. Investors are encouraged to contact the firm for potential class action participation.
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
ADMA Biologics shares fell 17% after the company lowered its outlook for fiscal year 2026, revising its revenue target down to $400M from $500M. The company also withdrew its long-term revenue guidance of $1 billion by 2029, citing ongoing dynamics in the plasma industry. Despite this, ADMA reiterated its FY24 outlook and provided a revised outlook for FY25 with slightly lower expected revenues.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. following allegations of misleading business information. The investigation stems from a short seller report claiming "channel stuffing" to inflate revenue, which led to a significant drop in ADMA stock. Shareholders who purchased ADMA Biologics securities are encouraged to contact the firm to inquire about joining a prospective class action lawsuit.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
The Rosen Law Firm is investigating potential securities class action claims against ADMA Biologics, Inc. (NASDAQ: ADMA) following allegations published by short seller Culper Research regarding "channel stuffing" to inflate revenue. Investors who purchased ADMA Biologics securities are encouraged to contact the firm to inquire about joining the prospective class action and potentially recovering losses. The firm highlights its experience in securities class actions and its track record of achieving significant settlements for investors.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. following allegations by short seller Culper Research of "channel stuffing" to inflate revenue growth. This led to a significant 16.6% drop in ADMA Biologics stock on March 24, 2026. The firm encourages investors who purchased ADMA securities to inquire about joining a prospective class action to recover losses.
ADMA Fraud Notice: ADMA Biologics is being Investigated for Securities Fraud after 29% Stock Drop -- Investors Reminded to Contact BFA Law
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics (NASDAQ:ADMA) for potential securities fraud. This comes after a Culper Research report alleged that ADMA Biologics engaged in channel stuffing to falsely report 20% revenue growth in 2025, when actual growth would have been a 3% decline. The news caused ADMA's stock to drop 29%, leading the firm to encourage affected investors to seek legal options.
ADMA Fraud Notice: ADMA Biologics is being Investigated for Securities Fraud after 29% Stock Drop -- Investors Reminded to Contact BFA Law
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics, Inc. (NASDAQ:ADMA) for potential federal securities law violations after a 29% stock drop. This investigation follows a Culper Research report alleging that ADMA Biologics engaged in a channel stuffing scheme to inflate its reported 2025 revenue growth. Investors who suffered losses are encouraged to contact BFA Law for information regarding their legal options.
A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations
ADMA Biologics (ADMA) stock is under scrutiny following short seller allegations of channel stuffing and impending legal investigations, causing significant stock price fluctuations. Despite long-term gains, the company's valuation faces challenges from legal risks, competitive pricing, and trimmed guidance. Analysts suggest a fair value of $20.93, indicating it may be undervalued, but this hinges on future growth and margin assumptions while legal issues remain unresolved.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Pomerantz LLP is investigating potential securities fraud claims against ADMA Biologics, Inc. ("ADMA") following a significant drop in its stock price. The investigation follows a short report by Culper Research alleging channel stuffing and undisclosed related party distribution, as well as a downgrade by Cantor Fitzgerald and ADMA's subsequent withdrawal of long-term financial guidance. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action.
ADMA Biologics Inc - Common Stock (NQ: ADMA)
This article compiles recent news headlines related to ADMA Biologics Inc. (NASDAQ: ADMA), covering topics such as earning reports, analyst ratings, market sentiment, short interest, and FDA approvals. It highlights the company's performance, including its revenue and adjusted EBITDA growth, and mentions its immunoglobulin products made from donated plasma. The news also touches on broader biotech sector trends and other related company news.
Here’s What Analysts Think About ADMA Biologics (ADMA)
Mizuho and Canaccord recently lowered their price targets for ADMA Biologics (ADMA) to $20 and $18, respectively, while maintaining Outperform/Buy ratings. This adjustment followed ADMA's Q1 2026 financial results, which saw revenues of $114.5 million, a 28% increase in ASCENIV revenue, but a 54% drop in BIVIGAM revenue. The article also mentions ADMA as a potential small-cap stock but suggests other AI stocks might offer greater returns.
ADMA Investor News: If You Have Suffered Losses in ADMA
The Rosen Law Firm has announced an investigation into potential securities claims for shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) following allegations of misleading business information. This comes after a short seller report claimed the company engaged in "channel stuffing" to inflate revenue, causing a significant stock drop. The firm is preparing a class action lawsuit and encourages affected investors to contact them for potential compensation.
Adma biologics director Jerrold Grossman buys $100,125 in stock
Jerrold B. Grossman, a director at ADMA Biologics, Inc., recently purchased 12,500 shares of the company's common stock for $100,125, at a price of $8.01 per share. This transaction occurred on May 12, 2026, when the stock was trading near its 52-week low, and follows a recent earnings report where the company missed analyst expectations. Grossman's direct and indirect holdings now total a significant number of shares, indicating his continued investment in the company.
ADMA Biologics (NASDAQ: ADMA) director adds 12,500 shares in open-market buy
ADMA Biologics director Jerrold B. Grossman recently purchased 12,500 shares of ADMA common stock at $8.01 per share in an open-market transaction on May 12, 2026. This purchase increased his direct holdings to 513,884 common shares, which includes RSUs and previously owned stock. Grossman also has several indirect holdings through various trusts and entities.
ADMA Investor News: If You Have Suffered Losses in ADMA
The Rosen Law Firm announced an investigation into potential securities claims against ADMA Biologics, Inc. (NASDAQ: ADMA) after a short seller alleged the company engaged in channel stuffing to inflate revenue growth, causing a 16.6% stock drop on March 24, 2026. Shareholders who purchased ADMA Biologics securities are encouraged to contact the firm to potentially join a class action seeking compensation for investor losses. The firm, known for its success in securities class actions, emphasizes its track record and resources for investors seeking counsel.
Adma Biologics director buys $100,125 of common stock
Dr. Jerrold B. Grossman, a director at ADMA Biologics, Inc., recently purchased 12,500 shares of the company's common stock for a total of $100,125. This transaction, reported on May 11, 2026, increased his direct holdings to 501,384 shares. Despite the purchase, ADMA stock is down 61% over the past year, and the company recently missed analysts' expectations for Q1 2026 earnings and revenue.
[Form 4] ADMA BIOLOGICS, INC. Insider Trading Activity
ADMA Biologics director Jerrold B. Grossman recently bought 12,500 shares of common stock at $8.01 per share in an open-market transaction, increasing his direct holdings to 501,384 shares. The filing also details his indirect holdings through various entities and his wife, as well as 10,690 restricted stock units (RSUs) granted in February 2026. This purchase indicates a positive sentiment from the insider regarding the company's stock.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. following allegations that the company may have issued materially misleading business information. This investigation comes after a short seller report claimed ADMA Biologics engaged in "channel stuffing" to inflate revenue growth, causing a 16.6% drop in its stock price on March 24, 2026. Investors who purchased ADMA Biologics securities are encouraged to contact the law firm to learn about joining a prospective class action to recover losses.
ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation
Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations after the company's stock fell over 24% on May 6, 2026. This drop occurred after ADMA Biologics withdrew its long-term financial guidance and followed a prior report alleging inflated growth and misleading business practices. Investors who have lost money are encouraged to contact the firm to explore potential loss recovery.
ADMA Investor News: If You Have Suffered Losses in ADMA
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. (NASDAQ: ADMA) after a short seller report alleged the company engaged in channel stuffing, causing a 16.6% stock drop. Investors who purchased ADMA Biologics securities are encouraged to contact the firm to potentially join a class action lawsuit seeking to recover losses. The firm emphasizes its experience and success in securities class action litigation.
$ADMA Investigation Reminder: ADMA Biologics Investigation on behalf of Investors is Ongoing – Contact BFA Law if You Lost Money
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics (NASDAQ:ADMA) for alleged violations of federal securities laws after a Culper Research report claimed the company's 2025 revenue growth was driven by a channel stuffing scheme. The report suggested that without this alleged scheme, ADMA Biologics would have seen a 3% revenue decline instead of the reported 20% growth, causing its stock to drop 29%. Investors who lost money are encouraged to contact BFA Law to explore their legal options.
ADMA Investor News: If You Have Suffered Losses in ADMA
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. (NASDAQ: ADMA) following allegations of misleading business information. This probe comes after a short seller report claimed ADMA engaged in channel stuffing, causing a 16.6% stock drop on March 24, 2026. The firm encourages investors who suffered losses to contact them regarding a prospective class action for compensation.
10 Best Healthcare Stocks to Buy for the Long Term
This article identifies ADMA Biologics Inc. (NASDAQ:ADMA) as one of the best healthcare stocks for long-term investment, noting its strong performance in Asceniv revenue despite an overall flat Q1 2026. Canaccord reiterated a Buy rating on ADMA, adjusting its price target to $18 from $21. The company's adjusted net income and EBITDA also showed significant year-over-year growth.
ADMA Biologics Stock Plunges As Legal Probes Escalate
ADMA Biologics Inc. (NASDAQ: ADMA) stock has declined significantly due to allegations of channel stuffing and subsequent legal investigations. Short-seller Culper Research claimed the company inflated its 2025 revenue growth by manipulating sales of its ASCENIV product, leading to multiple securities fraud investigations by law firms. Despite strong financial fundamentals, the ongoing legal and reputational risks are expected to keep the stock volatile and trading at a discount.
Lowey Dannenberg, P.C. is Investigating ADMA Biologics
Lowey Dannenberg, P.C. is investigating ADMA Biologics (NASDAQ: ADMA) for potential federal securities law violations. This investigation follows a report by Culper Research, alleging that ADMA Biologics engaged in "channel stuffing" in 2025 by offering rebates and extended payment terms to a distributor to inflate reported revenue growth. Investors with losses exceeding $50,000 are encouraged to contact the firm.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. following allegations that the company issued misleading business information, which reportedly caused a significant stock drop. Investors who purchased ADMA Biologics securities are encouraged to contact the law firm to inquire about joining a prospective class action seeking compensation. The investigation stems from a report by short seller Culper Research, accusing ADMA Biologics of "channel stuffing" to inflate revenue growth.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
Rosen Law Firm has announced an investigation into potential securities claims against ADMA Biologics, Inc. following short seller allegations of channel stuffing to inflate revenue growth, which caused a significant drop in ADMA's stock price on March 24, 2026. The firm encourages investors who purchased ADMA Biologics securities to contact them to inquire about joining a prospective class action lawsuit and seeking compensation. They highlight their track record in securities class actions as a reason for investors to choose their firm.
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors. This comes after a short seller report alleged the company engaged in "channel stuffing" to inflate revenue, causing an immediate 16.6% drop in stock price on March 24, 2026. The firm encourages affected investors to join a prospective class action seeking compensation.
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
ADMA Biologics (ADMA) saw its stock decline by over 17% after reducing its full-year 2026 outlook. The company also withdrew its long-term guidance, citing "uncertainty in the competitive landscape." This announcement led to a significant drop in its stock price during midday trading.
ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors
Kehoe Law Firm, P.C. is investigating potential securities claims against ADMA Biologics, Inc. following reports of aggressive competitive pricing tactics impacting the company's Q1 2026 results. The stock price of ADMA Biologics (NASDAQ: ADMA) dropped sharply after the announcement, coupled with an earlier report from Culper Research alleging "channel stuffing." Investors are encouraged to contact the firm for a free evaluation of potential legal claims.
ADMA Biologics Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
Block & Leviton is investigating ADMA Biologics, Inc. for potential securities fraud after the company withdrew its long-term financial guidance and its stock dropped over 24%. This follows a Culper Research report alleging inflated growth due to channel stuffing. Investors who lost money are encouraged to contact Block & Leviton to explore recovering their losses.
ADMA BIOLOGICS, INC. 1Q 2026: Revenue $114.49M, EPS $0.19— 10-Q Summary
ADMA Biologics, Inc. reported its first-quarter 2026 results, showing essentially flat revenue but improved profitability compared to the previous year. This performance was attributed to increased ASCENIV sales and operational efficiency gains, which significantly boosted net income and diluted EPS. The company also highlighted strategic actions to optimize production capacity and plasma sourcing, alongside increased R&D investment for SG-001.
BREAKING: ADMA Biologics Shares Fall Over 24%; Investors
Block & Leviton LLP is investigating ADMA Biologics, Inc. (Nasdaq: ADMA) for potential securities law violations after its shares fell over 24% following the company's withdrawal of long-term financial guidance. The share price drop came amid evolving market dynamics and a prior report alleging inflated growth due to channel stuffing. Block & Leviton is encouraging investors who have lost money to contact them to discuss potential recovery.
Earnings Flash (ADMA) ADMA Biologics, Inc. Reports Q1 Revenue $114.5M, vs. FactSet Est of $140.0M
ADMA Biologics, Inc. reported its Q1 revenue at $114.5 million, falling short of the FactSet estimate of $140.0 million. The company is a commercial biopharmaceutical firm that manufactures, markets, and develops specialty biologics for immunodeficient patients and those at risk for certain infectious diseases. Its product portfolio includes BIVIGAM, ASCENIV, and NABI-HB, all FDA-approved plasma-derived biologics.
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
ADMA Biologics announced that the FDA has approved its supplemental Biologics License Application (BLA) for ASCENIV™, expanding its indication to include pediatric primary humoral immunodeficiency (PI) patients aged two years and older. This approval allows ADMA to address the treatment needs of younger immune-compromised patients. Previously, ASCENIV™ was indicated for PI patients 12 years and older, and this expansion is a result of successfully completed pediatric clinical trials.
BREAKING: ADMA Biologics Shares Fall Over 24%; Investors
ADMA Biologics' stock fell over 24% after the company withdrew its long-term financial guidance, citing competitive market dynamics. This follows a previous report alleging inflated growth due to channel stuffing. Block & Leviton is investigating potential securities law violations and is encouraging investors who have lost money to contact them for recovery options.
ADMA Biologics Inc (ADMA) Stock Falls on Q1 2026 Earnings
ADMA Biologics Inc (ADMA) reported its Q1 2026 earnings, with revenue of $114.5 million falling short of consensus estimates and diluted EPS of $0.19 also slightly missing expectations. Despite a significant increase in gross profit and net income, the stock declined by 23.65% after the release. Insider trading activity shows more sales than purchases, while institutional investors show mixed movements in their holdings.
12 Health Care Stocks Moving In Wednesday's After-Market Session
This article lists 12 healthcare stocks that experienced significant movement during Wednesday's after-market session, categorized by gainers and losers. Several companies, including Agilon Health, ADMA Biologics, LifeMD, MannKind, and Alvotech, released their Q1 earnings today, contributing to their stock fluctuations. The article provides details on the stock price changes and market capitalization for each listed company.
ADMA Biologics (ADMA) lifts Q1 2026 margins as ASCENIV grows 28% while revenue stays flat
ADMA Biologics reported flat revenue of $114.5 million in Q1 2026 but significantly increased profitability, with gross margin expanding to 71% and GAAP net income rising to $45.3 million. This was primarily driven by 28% growth in ASCENIV sales, offsetting declines in other products. The company updated its full-year 2026 outlook due to competitive pressures in the U.S. immunoglobulin market and withdrew longer-term guidance.
ADMA kept revenue flat while ASCENIV sales climbed 28% in Q1
ADMA Biologics reported flat revenue for Q1 2026 at $114.5 million, with ASCENIV sales increasing by 28% year-over-year to $97.5 million, while BIVIGAM sales declined significantly. Despite market competitive dynamics and distributor inventory pressures causing near-term top-line challenges and prompting ADMA to withdraw its long-term guidance, the company showcased strong profitability with Adjusted Net Income up 22% and Adjusted EBITDA up 24%. ADMA expressed confidence in ASCENIV's continued growth, driven by strong demand fundamentals.
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
ADMA Biologics reported its first-quarter 2026 financial results, with total revenue flat year-over-year at $114.5 million, despite a 28% increase in ASCENIV revenue and a 54% decrease in BIVIGAM revenue. The company achieved 22% growth in Adjusted Net Income and 24% growth in Adjusted EBITDA, while also generating $58 million in cash from operations. ADMA updated its full-year 2026 outlook, reflecting evolving market dynamics, but expressed confidence in ASCENIV's growth driven by strong demand fundamentals.
Adma Biologics: Q1 Earnings Snapshot
Adma Biologics Inc. (ADMA) reported a first-quarter net income of $45.3 million, or 19 cents per share, on revenue of $114.5 million. The company, which develops infectious disease drugs, forecasts full-year revenue between $530 million and $560 million. Despite the earnings report, Adma Biologics shares have decreased 45% since the beginning of the year and 56% over the last 12 months.
ADMA Biologics earnings on deck amid channel stuffing scrutiny
ADMA Biologics is facing scrutiny over channel stuffing allegations as it prepares to report Q1 earnings. Investors will be looking for management's response to these claims, which have caused the stock to drop significantly. The FDA's recent approval for ASCENIV's expanded label provides a potential growth catalyst, but the company must demonstrate genuine demand rather than inventory build-up.
